All In Biotech

Drug Trial Radar · NCT05411237

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Sep 2029

Study completion Sep 2030

Sponsor

Lead sponsor
AIDS Malignancy ConsortiumResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jun 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma (KS) in people living with HIV (human immunodeficiency virus) in sub-Saharan Africa. Patients with HIV-related KS will receive either PTX or PLD once every 3 weeks for a total of six cycles.

Conditions

  • Kaposi Sarcoma
  • HIV-1-infection
  • AIDS-related Kaposi Sarcoma

Interventions

  • Pegylated liposomal doxorubicinDrug

    PLD 20 mg/m2 on Day 1 of every 21-day cycle

  • PaclitaxelDrug

    PTX 100 mg/m2 on Day 1 of every 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival at 48 weeksTime frame: 48 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.